On September 9, 2026 Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, reported the promotion of Chris Clark, CFA, to Chief Financial Officer. Mr. Clark joined Electra in December 2025 as Executive Vice President, Strategy and Finance, bringing with him more than two decades of life sciences investment experience.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since joining Electra, Chris has played an instrumental role in shaping our capital strategy and strengthening our position within the healthcare investment community," said Kathy Dong, Pharm.D., MBA, President and Chief Executive Officer of Electra Therapeutics. "As we advance ipsoprubart through its global registrational program in secondary hemophagocytic lymphohistiocytosis and expand our clinical pipeline of precision immune cell depletion therapies, Chris’ leadership, institutional investment experience, and understanding of the capital markets will be critical to guiding our financial and business strategies through our next phase of growth."

Mr. Clark has more than 20 years of expertise evaluating and financing biopharmaceutical companies across therapeutic areas, stages of development and market capitalizations. Prior to joining Electra, he spent 18 years at RS Investments, a subsidiary of Victory Capital, where he served as Portfolio Manager and Equity Analyst focused on healthcare and led investments in biopharmaceutical and life sciences companies across multiple fund strategies. Earlier in his career, Mr. Clark served as a Research Associate at TIAA-CREF, where he focused on global pharmaceutical companies, and as a Research Assistant at Dresdner RCM. He earned a Bachelor of Arts in Economics from the University of Virginia and is a Chartered Financial Analyst (CFA).

"I am honored to step into this new and expanded role, working alongside our talented and passionate team to advance Electra’s strategic and financial priorities, progress our programs, and ultimately serve the many patients with immune-mediated diseases and cancer who are in need of better treatment options," said Mr. Clark.

(Press release, Electra Therapeutics, SEP 9, 2026, View Source [SID1234670667])

On September 9, 2026 Alivexis, Inc. ("Alivexis"), a preclinical-stage computation-driven drug discovery company, reported it will present our recent data from MOD-D, one of our drug discovery programs, at the 85th Annual Meeting of the Japanese Cancer Association, to be held September 24th-26th in Kyoto, Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our presentation will focus on the pharmacological profile of AL003626, Alivexis’ highly potent novel WDR5 inhibitor, and its therapeutic activity in various MYC-driven cancers, in the session entitled "Novel Therapeutic Strategies Targeting Cancer Vulnerabilities".

Alivexis’ presentation details are as follows:
Title: Development of AL003626, a Novel WDR5 Inhibitor Targeting the WDR5–MYC Axis for the Treatment of MYC-Driven Cancers
Presentation Number: E-1063
Authers: Masahiro Matsuki, Takafumi Shimizu, Taisuke Takahashi, Blake Mertz, William Sinko, and Yoh Terada
Presentation Date/Time: Thursday, September 24th, 12:50-14:05 (JST)
Venue: Kyoto International Conference Center, Room 12 (2F Room J)

(Press release, Alivexis, SEP 9, 2026, View Source [SID1234670666])

On September 9, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued advancement of Ampligen (rintatolimod) in pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the CEO Corner, Equels discusses the significant challenges associated with pancreatic cancer, including its highly immunosuppressive – or "cold" – tumor microenvironment, which can prevent the immune system from mounting an effective response and has historically limited the effectiveness of many immunotherapy approaches.

Ampligen, AIM’s investigational TLR3 agonist, is designed to activate innate immunity and help reshape the tumor microenvironment, potentially making tumors more responsive to checkpoint inhibition. Based on existing data, AIM believes Ampligen may have a broad-spectrum synergistic effect with both PD-1 checkpoint inhibitors such as pembrolizumab, and PD-L1 checkpoint inhibitors such as durvalumab.

This scientific rationale is being evaluated through the Company’s ongoing Phase 2 DURIPANC study, which is assessing Ampligen in combination with AstraZeneca’s durvalumab as maintenance therapy following standard-of-care treatment in patients with pancreatic cancer. AIM believes the study has the potential to provide important insights into patient selection, biomarker identification and the characteristics of patients who may derive the greatest clinical benefit, helping inform the design of a potential future pivotal development program.

"Pancreatic cancer remains one of oncology’s most difficult diseases, in large part because its immunosuppressive tumor microenvironment creates significant barriers to effective immune responses," said Equels. "Our strategy with Ampligen is designed to address that underlying biology by activating innate immunity and potentially making these tumors more responsive to checkpoint inhibition. As we continue to advance DURIPANC, biomarker research and our broader clinical development strategy, we believe the data generated can further strengthen our understanding of Ampligen’s mechanism of action and its potential role in addressing this significant unmet medical need."

Beyond DURIPANC, AIM continues to build a broader body of scientific and clinical evidence supporting Ampligen through collaborations with leading institutions, ongoing biomarker research, expansion of its intellectual property portfolio and continued regulatory engagement.

Looking ahead in DURIPANC, the Company expects primary endpoint analyses, continued biomarker evaluations and overall survival follow-up. It also plans future regulatory interactions to provide additional opportunities to evaluate Ampligen’s potential and refine AIM’s long-term pancreatic cancer development strategy.

The latest CEO Corner segment is now available on the Company’s website here.

(Press release, AIM ImmunoTech, SEP 9, 2026, View Source [SID1234670665])

On September 9, 2026 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, reported the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. ("Exelixis").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment from Exelixis. XB404, built with Adagene’s SAFEbody masking technology, is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects. An additional payment to Adagene was triggered by the selection of candidates for another SAFEbody antibody-drug conjugate (ADC) program. Exelixis has the right to utilize Adagene’s SAFEbody technology platform to generate masked monoclonal antibodies for the development of masked ADC candidates.

Adagene is eligible to receive development and commercialization milestones and royalties on net sales of products developed.

(Press release, Adagene, SEP 9, 2026, View Source [SID1234670664])

On September 9, 2026 Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, reported that the Data Safety and Monitoring Board (DSMB) has completed its final assessment of the ongoing Phase I-part of the CARMA clinical study with the CAR T-cell therapy, ELC-301, for the treatment of B-cell lymphoma. The DSMB recommended the highest dose for continuation of the study into Phase IIa.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dose-escalation study, conducted in collaboration with Uppsala University as the co-sponsor, consists of two parts: a dose-escalation study (Phase I) with 12 patients, which is now complete, and a dose-expansion study (Phase IIa) with 6 patients. The cell therapy ELC-301 incorporates the iTANK platform technology, which, through its parallel immune activation, aims to provide a broader and more effective attack on cancer cells.

No dose limiting toxicities have been reported in Phase I. The Data Safety and Monitoring Board (DSMB) has, after reviewing the safety data, recommended the highest dose level as the Phase IIa dose. Once approval from the Swedish Medical Products Agency (MPA) has been received, Phase IIa patients will be treated at the highest dose level.

The latest data reported from the CARMA study, press released on August 11, showed that among the eleven patients evaluated, all had achieved disease control (no disease progression) one month after treatment, and 91 percent (10/11) had obtained an objective tumor response, including six patients (55 percent) with complete metabolic response (disease-free status). Of these, four patients remained disease-free, one for at least 18 months and one for at least 12 months. The company will provide an update of preliminary efficacy data from all 12 patients in the Phase I-part of the study when the final patient in Phase I has undergone the one-month evaluation.

"Built on the accumulated efficacy signals we have seen so far in Phase I, the DSMB’s positive recommendation strengthens our confidence in ELC-301. We can now proceed with the Phase IIa part of the CARMA study as soon as possible after MPA approval. This brings us one step closer to offering a new treatment option to patients with limited alternatives. I look forward to sharing the complete Phase I data in due course", says Elicera’s CEO, Johan Liwing.

(Press release, Elicera Therapeutics, SEP 9, 2026, View Source,c4393670 [SID1234670641])